ClinicalTrials.gg
TerminatedNCT04932915PREVENTUpdated Feb 21, 2022

Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19

A Phase 2 interventional study of Niclosamide and Placebo in Covid19, sponsored by UNION therapeutics. Terminated at 3 sites in Germany. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-02-21.

Sponsored by UNION therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Failure of recruiting patients

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 226 studies in COVID-19 with a site in Germany — 21 open to participants now, 27 under way, 7 of them phase 3. COVID-19 · Germany.

Enrollment
122nd of 130
4 · median 135
Started
2021
with 59 others
Phase 2
28 of 226
none open now
Registered
153rd of 226
by date

Among the 226 studies in COVID-19 with a site in Germany, this one is the 122nd largest by enrollment of the 130 interventional ones that give a count, is one of 60 that started in 2021, is one of 28 in phase 2, and was the 153rd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

21 of the 226 studies in COVID-19 with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in COVID-19 with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of UNI91103 intranasal spray for treatment of coronavirus disease 2019 (COVID-19) in asymptomatic or mildly symptomatic adults.

03

Conditions studied

  • Covid19

Browse trials for

04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female aged ≥45 and \<80 years
  • Subject is tested to confirm infection with SARS-CoV-2 on a sample taken within 3 days before randomization
  • Subject is either without symptoms or has 1 or more of the following symptoms: Stuffy or runny nose, Sore throat, Loss of taste, Loss of smell, Headache.

None of the symptoms should have been present >5 days.

Exclusion criteria

Exclusion Criteria:

  • Subject has an underlying condition that may interfere with intranasal administration of the IMP (e.g., chronic ulcers in the nose).
  • Subject has symptoms suggesting engagement of the lower respiratory tract or a systemic engagement
  • Subject has an active or acute infection other than SARS-CoV-2
  • Subject has another member of the same household recruited to this study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    UNI91103 intranasal spray 1%

    UNI91103 intranasal spray 1%, BID, 10 consecutive days

    Drug: Niclosamide

  • Placebo comparator
    Placebo

    Placebo intranasal spray, BID, 10 consecutive days

    Drug: Placebo

Interventions

  • Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.

  • DrugPlacebo

    The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with worsened symptoms any time from Day 3 to Day 10 compared with baseline

    Worsening is assessed by the Food and Drug Administration (FDA) COVID-19 Symptom Questionnaire, assessing severity of symptoms over the past 24 hour period.

    Time frame: Day 3 to Day 10

Secondary outcomes

  1. Proportion of subjects with worst intensity/grade up to Day 10 and up to Day 15 in any single symptoms in the 3 domains of the FDA COVID-19 questionnaire

    Assessed by the FDA COVID-19 symptom questionnaire divided into 3 domains - Items 1 to 10, items 11 to 12 and items 13 to 14

    Time frame: Day 10 and up to Day 15

  2. Proportion of subjects reporting the following number of symptoms with worst intensity/severe grade: ≥ 1 symptom, ≥ 2 symptoms, ≥ 3 symptoms, etc.

    Assessed by the FDA COVID-19 symptom questionnaire looking at the individual symptoms

    Time frame: Any time point

  3. Proportion of subjects with worsened symptoms at Day 15 compared with baseline.

    Worsening is assessed by the FDA COVID-19 Symptom Questionnaire, which is a self reported questionnaire assessing severity of symptoms over the past 24 hour period.

    Time frame: Day 15

  4. Change from baseline in each single symptom score

    Assessed by the FDA COVID-19 symptom questionnaire looking at the individual symptoms

    Time frame: Days 10, 15 and 30

  5. Proportion of subjects who are asymptomatic on Day 10

    Assessed by the FDA COVID-19 symptom questionnaire

    Time frame: Day 10

  6. Proportion of subjects requiring visits to urgent care (UC) or emergency department (ED) facilities, or hospitalization because of signs or symptoms of COVID-19

    Number of visits to urgent care (UC) or emergency department (ED) facilities, or hospitalization is assessed by a self developed questionnaire

    Time frame: Day 10, 15 and 30

  7. Proportion of subjects admitted to intensive care units (ICU) and/or died

    Assessed by WHO 11-point Ordinal Scale

    Time frame: At screening, Day 1, and every other day through Day 10, and again at Day 15 and Day 30

  8. Change from baseline in SARS-CoV-2 viral load at Day 5 and Day 10

    Assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR)

    Time frame: Day 5 and Day 10

07

Study locations

3 sites
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, Germany
  • Klinische Forschung Hamburg GmbH
    Hamburg, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jan 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2021
First posted
Jun 21, 2021
StartActual
Sep 3, 2021
Primary completionActual
Jan 10, 2022
CompletionActual
Jan 10, 2022
Last update
Feb 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04932915
Lead sponsor
UNION therapeutics
Responsible party
Sponsor
First posted
Jun 21, 2021
Start date
Sep 3, 2021
Primary completion
Jan 10, 2022
Completion
Jan 10, 2022
Last update
Feb 21, 2022

Study contacts

Peter Heymer, MD
principal investigator · Klinische Forschung Dresden GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niclosamide

Start the discussion